Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Tofacitinib in Vitiligo
NCT05293119Phase 1Unknown
- Sponsor
- Pi Research Consultancy Center
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of INN-04-01 in Vitiligo (2 arms), sponsored by Pi Research Consultancy Center. Primary endpoint: Vitiligo Area Scoring Index at 12 weeks. Status: unknown.
02
Drugs
INN-04-01
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT05293119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293119.